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Objective: Symptoms, mortality, and costs of chronic obstructive pulmonary disease (COPD)
concentrate among patients who have been hospitalised with the disease. Nevertheless, no
solid estimates exist of trends in the prevalence of this condition. This study aimed to inves-
tigate age- and sex-specific trends in the prevalence of hospitalisation-required COPD.
Method: Using national registers, a cohort trend study was conducted covering the entire
Danish population (5.4 million citizens) from 1994 to 2009. Subjects were classified as preva-
lent in the period between first COPD hospitalisation and either death, migration, or the
end of an individual 8-year period with no COPD hospitalisations.
Results: In 2009 in Denmark the prevalence of hospitalisation-required COPD was: For males
45e59 years 0.36%, 60e74 years 1.37%, 75e84 years 4.13%, 85þ years 4.33%, and for females:
45e59 years: 0.49%, 60e74 years: 1.74%, 75e84 years: 3.96%, 85þ years: 2.99%. During the
period from 2002 to 2009 the overall prevalence remained constant. However, among
subjects aged above and below 75 years, respectively, substantial decreases and increases
were found. An increasing female prevalence exceeded male prevalence, which decreased.
Conclusion: Some 4% of the Danish population aged above 75 years have been hospitalised
with COPD. During the period from 2002 to 2009 the overall prevalence of hospitalisation-
required COPD remained constant. However, significant age-specific trends indicate that
within a few years, ageing of birth cohorts with low COPD prevalence will lead to a substantial
decrease in the prevalence of hospitalisation-required COPD.
ª 2012 Elsevier Ltd. All rights reserved.550 3967; fax: þ45 6550 3980.
h.sdu.dk (J. Lykkegaard).
2 Elsevier Ltd. All rights reserved.
12.06.004
On the crest of a wave 1397Introduction registers.
25 We linked individual health administrative dataSolid estimates of the prevalence of major chronic diseases
provide important guidance to planners of the dimensions
and structure of healthcare systems. COPD is among the
most frequent causes of hospitalisation.1,2 Among COPD
patients, admission to hospital indicates higher levels of
costs, symptoms, and reduction in quality of life.1,3e6 Also,
patients who have been hospitalised with COPD have more
exacerbations and more comorbidity. Hence, readmissions
are frequent. Furthermore, regardless of lung function
impairment, COPD hospitalisation dramatically increases
mortality.7
The rate of COPD hospitalisations in France has been
increasing8 while in Denmark and the US it increased rapidly
until around year 2000 after which it has been slightly
decreasing.9e11 Because of high mortality and readmission
rates, the above-mentioned trends do not provide infor-
mation about the prevalence of hospitalisation-required
COPD (HRCOPD), i.e. the prevalence of subjects who have
been hospitalised with COPD.
In developed countries, among adults aged 45 years and
above, population surveys estimate that the prevalence of
severe COPD is 1e2%, while the prevalence of any stage
COPD is about 10%.12e19 Trend studies of COPD prevalence
are few. Repeated cross-sectional surveys from Finland and
Spain, and a Canadian cohort study of healthcare claims,
indicate that COPD prevalences are constant or maybe
decreasing.20e22
Although elderly people carry most of the COPD burden,
previous prevalence studies tend to focus on middle-aged
subjects.12e22 Among the above studies, some report lower
response rates among the elderly, while others simply
exclude subjects above a certain age. The mean age of
first-time COPD hospitalised subjects is about 75 years.10
Nevertheless, no studies provide detailed information
about subjects above this age.
This study aims to investigate trends in the age- and sex-
specific prevalence of hospitalisation-required COPD.Methods
Data sources
We conducted a register-based time trend analysis covering
the entire Danish population (5.43 million in 200823) from
1994 to 2009.
In Denmark more than 99% of admissions with COPD are
to public hospitals.10 COPD hospitalisations most frequently
occur by referral from a medical doctor, typically a general
practitioner, but in emergency cases admissions without
referral also occur. The Danish healthcare services are free
of charge and with equal access for all citizens.
Since 1977, the Danish National Patient Registry has
recorded administrative data from all admissions to Danish
hospitals.24 From 1994 and onwards diagnoses are classified
according to the International Classification of Diseases
10th revision (ICD-10). All data are registered with the
patient’s unique civil registration number, which allows
data linkage on an individual level between all nationalwith data from the Demographic Register obtaining dates of
birth, death, and migrations to or from Denmark. For the
years 2002e2009, this register also provided age- and sex-
specific numbers of subjects and deaths in the total
Danish population. Our study received approval from the
Danish Data Protection Agency (No. 2009-41-3337).
Definition of COPD hospitalisation
COPD hospitalisation was defined as any hospitalisation with
either ICD-10 codes J41e44 (COPD, chronic bronchitis, or
emphysema) as primary diagnosis or with J13e18 (pneu-
monia) or J96 (respiratory failure) as primary diagnosis
combined with either of J41e44 as a secondary diagnoses.24
HRCOPD incidence and prevalence
Between January 1994 and January 2009 all Danish COPD
hospitalised subjects and dates of each subjects’ COPD
hospitalisations were identified. First-time COPD hospital-
isations (incident HRCOPD) were defined as any COPD hos-
pitalisation of a subject who had not been hospitalised with
COPD within a period of 8 years before the hospitalisation
in question. Correspondingly, subjects were classified as
prevalent with HRCOPD in the period between first COPD
hospitalisation and either death, migration, or the end of 8
years of individual follow-up with no COPD hospitalisations
(Table 1).
By use of individual 8-year look-back periods, incidence
and prevalence were determined equally through all
observation years. This approach enabled us to estimate
reliable time trends. However, it restricted us from esti-
mation of incidence and prevalence before January 2002.
The 7-year study period and the longer 8-year look-back
period were chosen because ICD-10 classified data were
only available from year 1994e2009 and we wanted both
unbiased trend estimates and to avoid the possibility of the
same subject being regarded as first-time hospitalised
twice in our study period. Furthermore, after 8 years of
readmission-free survival, COPD readmissions are very rare
(Table 1).
Mortality
All deaths of subjects with HRCOPD were identified. For
each year, in each age- and sex-specific strata of the
HRCOPD prevalent population, by dividing the number of
deaths by the sum of prevalent subjects by 1 January and
the incident subjects of the year in question the mortality
rate was estimated. For each year, dividing the total
number of deaths in the Danish population minus the deaths
in the HRCOPD population by the total Danish population
minus the sum of the prevalent and incident subjects of the
year in question equalled the annual mortality rates of the
population without HRCOPD.
Statistics
By use of direct age- and sex-standardisation to the Danish
2009 population, the 2002 and 2009 COPD prevalence
Table 1 Entry and exit of the population of Danes with HRCOPD 2002e2009.
2002 2003 2004 2005 2006 2007 2008 2009
Females
45e74 yrs
Prevalence 1 Jan 10,538 10,690 10,770 10,831 10,902 10,725 10,512 10,415
New cases þ2185 þ2121 þ1992 þ2110 þ1860 þ2012 þ1940
Mortality(%) 1146(9) 1106(9) 981(8) 982(8) 976(8) 1068(8) 944(8)
Migrations 6 9 0 7 3 6 3
Aged 45eaged 75 628 629 644 675 615 688 634
End of period 253 297 306 375 443 463 456
Population 1 Jan 917,383 926,050 934,984 944,648 993,403 966,717 978,480 993,517
Females
75þ yrs
Prevalence 1 Jan 6834 7125 7363 7670 8001 8196 8394 8578
New cases þ1505 þ1525 þ1525 þ1620 þ1621 þ1734 þ1751
Mortality(%) 1700(20) 1718(20) 1647(19) 1769(19) 1804(19) 1938(19) 1957(19)
Migrations 1 1 3 3 2 1 1
Aged 75 þ695 þ680 þ688 þ749 þ687 þ765 þ704
End of period 208 248 256 266 307 362 313
Population 1 Jan 239,365 237,968 237,296 236,843 236,625 236,033 235,525 235,357
Males
45e74 yrs
Prevalence 1 Jan 7879 7923 7932 7959 7940 7897 7876 7821
New cases þ1788 þ1804 þ1699 þ1706 þ1685 þ1725 þ1681
Mortality(%) 1028(11) 1082(11) 943(10) 915(9) 929(10) 915(10) 956(10)
Migrations 3 4 6 12 2 5 8
Aged 45eaged 75 472 509 466 539 480 484 441
End of period 241 200 257 259 317 342 331
Population 1 Jan 895,709 906,138 916,010 926,489 938,412 950,304 963,591 979,066
Males
75þ yrs
Prevalence 1 Jan 5680 5797 5826 5916 6099 6148 6220 6217
New cases þ1471 þ1447 þ1428 þ1408 þ1399 þ1567 þ1420
Mortality(%) 1734(24) 1797(25) 1680(23) 1648(23) 1671(22) 1791(23) 1694(22)
Migrations 1 0 2 1 2 2 2
Aged 75 þ525 þ543 þ517 þ595 þ535 þ538 þ488
End of period 144 164 173 171 212 240 215
Population 1 Jan 139,968 140,484 141,630 142,600 144,008 145,395 147,011 148,982
Mortality gives the number of deaths among the prevalent and incident cases in total and as percentage of the sum of prevalent and
incident subjects. “Aged 45eaged 75” gives the number of prevalent subjects who turned 45 years during the year minus the number of
prevalent subjects who turned 75 years. End of period gives the number of subjects who exit the prevalent population because they have
lived for 8 years after their first COPD hospitalisation with no further COPD hospitalisations.
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adjusted logistic regression, with calendar year as the
primary independent variable, trends in prevalence were
estimated. Coefficient plots and likelihood tests of frac-
tional polynomials confirmed that it was reasonable to use
year as a continuous variable without transformation.
Likewise, by use of logistic regression trends in the
mortality of the populations with and without HRCOPD
were estimated. All analyses were performed using STATA
Release 10.1 (STATACorp, College Station, TX, USA).Results
In January 2009 in Denmark 33,031 subjects above 45 years
of age had at some point been hospitalised with COPD
(Table 1). This corresponds to an overall HRCOPD preva-
lence proportion of 1.36%. For males the age-specific
prevalences were: 45e59 years 0.36%, 60e74 years 1.37%,
75e84 years 4.13%, 85þ years 4.33%, and for females:
45e59 years 0.49%, 60e74 years 1.74%, 75e84 years 3.96%,
85þ years 2.99% (Table 2).
In 2009, HRCOPD prevalence increased with age until the
age of around 90 years for males and 80 years for femalesafter which it decreased with increasing age. Seven years
before, in 2002, in both sexes the prevalences peaked at
ages about 7 years earlier. A similar pattern was observed in
the age- and sex-specific incidence rates of HRCOPD, while
the mortality of subjects with HRCOPD increased with
increasing age throughout life (Fig. 1).
During the period from year 2002e2009, the overall
prevalence of HRCOPD remained constant. However,
according to age and sex highly significant trends were
found (Fig. 2 & Table 2). The prevalence gradually
decreased among males and subjects aged below 75 years,
while it increased in the age groups above 75 years and
among females. The most extreme changes were the
prevalence among females aged 60e74 years decreasing
20%, while among females aged above 75 years increasing
more than 30%. For males aged 60e74 years it decreased
25% while it increased 12% in the age group above 85 years
of age. The overall prevalence among females increasingly
exceeded the one of males both in absolute and relative
numbers (Table 2).
During the period from 2002 to 2008, among subjects 45
years and above with HRCOPD, the age- and sex-adjusted
mortality decreased: OR 0.981 per year (CI 0.976e0.987),
but among subjects without HRCOPD the adjusted
Table 2 Trends in the Danish prevalence of HRCOPD 2002 to 2009.
2002 2009 Change: 2002 to 2009
HRCOPD Population PP HRCOPD Population PP POR 2009/2002 (CI 95%)
Females
45-59 2640 557,276 0.47% 2682 548,449 0.49% 1.04 (0.99-1.10)
60-74 7898 360,107 2.19% 7733 445,068 1.74% 0.80* (0.77-0.82)
75-84 5271 168,956 3.12% 6313 159,587 3.96% 1.28* (1.24-1.33)
85þ 1563 70,409 2.22% 2265 75,770 2.99% 1.36* (1.28-1.45)
All ages 17,372 1,156,748 1.51% Std 18,993 1,228,874 1.55% 1.04 a* (1.02-1.06)
Males
45-59 1862 566,848 0.33% 2020 554,915 0.36% 1.11* (1.05-1.19)
60-74 6017 328,861 1.83% 5801 424,151 1.37% 0.75* (0.72-0.78)
75-85 4568 111,388 4.10% 4802 116,296 4.13% 1.01 (0.97-1.05)
85þ 1112 28,580 3.89% 1415 32,686 4.33% 1.12* (1.03-1.21)
All ages 13,559 1,035,677 1.36% Std 14,038 1,128,048 1.24% 0.93 a* (0.90-0.95)
Overall, y
45-59 4502 1,124,124 0.40% 4702 1,103,364 0.43% 1.07 s* (1.03-1.12)
60-74 13,915 688,968 2.02% 13,534 869,219 1.56% 0.78 s* (0.76-0.80)
75-84 9839 280,344 3.51% 11,115 275,883 4.03% 1.15 s* (1.12-1.19)
85þ 2675 98,989 2.70% 3680 108,456 3.39% 1.26 s* (1.20-1.32)
All ages 30,931 2,192,425 1.44% Std 33,031 2,356,922 1.40% 0.99aþs (0.98-1.01)
Analysed using logistic regression. Abbreviations: HRCOPD, subjects with hospitalisation-required COPD; PP, Prevalence Proportion;
POR, Prevalence Odds Ratio; CI, confidence interval; Std Standardised to the Danish 2009 population; a adjusted for age; s adjusted for
sex; 2009/2002 comparing 2009 with 2002; *p<0.001.
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per year (CI 0.974e0.976).Discussion
This study found that 1.36% of the Danish population above
45 years of age have been hospitalised with COPD. Most
COPD hospitalised patients have severe stages of the
disease,12,26 and patients with severe COPD are frequently
hospitalised. Hence, our register-based findings correlate
well with the population surveys, which estimate a 0.8e2%
prevalence of severe COPD in the Northern European adult
population.12e15 Also, the increasing proportion of females
among patients with HRCOPD correlates with previous
findings.
In contrast, to our knowledge the dramatic differences
between the prevalence trends among subjects aged above
and below 75 years have not previously been demonstrated.
Furthermore, it is interesting that the prevalence and
incidence of HRCOPD increase with increasing age only until
a certain age, above which they decrease. These two
effects cause the prevalence and incidence graphs to
appear like rolling waves (Fig. 1). We believe that these
rolling waves are mainly caused by differences in the total
airway exposure throughout life in different birth cohorts.
The total Danish tobacco consumption per inhabitant
increased rapidly after World War Two. It peaked between
1958 and 1977, after which it has significantly decreased.27
Hence, in their youth the birth cohort who turned 90 years
in 2002 were not as exposed to tobacco as the birth cohort
who turned 80 years the same year. Therefore, considering
that most people start smoking before the age of 35 years itis likely that in 2002, despite the excess of life years,
cumulated the 90-year-olds had less tobacco exposure than
the 80-years-olds. This probably explains why they had
lower prevalence and incidence of HRCOPD. Furthermore,
ageing of the 80-year-olds of 2002, with high levels of
tobacco exposure, may be what caused the explosive
increase in the incidence and prevalence of HRCOPD among
87-year-olds between 2002 and 2009 (Fig. 1). Likewise in
the beginning of the wave, the decrease between 2002 and
2009 in HRCOPD among 60e75 year-olds may be due to
increasingly lower exposure to the Danish tobacco epidemic
from 1958 to 1977.
Previous studies have found that compared to birth
cohorts before and after, Danish women born between 1915
and 1945 have an excess mortality, which is mainly from
smoking-related diseases.28 This supports the fact that
a wave of birth cohorts with high prevalence of COPD is
rolling over Denmark.
In the past 99 years, besides from smoking, many other
changing occupational and environmental airway exposures
may also have contributed to causing the present birth
cohort differences in incidence and prevalence of
HRCOPD.29 In Denmark, during the period from 1930 to 1970
crafts and industry was the economic sector employing
most people.23 Furthermore, among the harmful airway
exposures of this booming third wave of Danish industrial-
isation many were later reduced by prohibition or regula-
tion. Hence, compared to the birth cohorts before and
after, among the highly HRCOPD prevalent birth cohorts
more subjects laboured in environments with harmful
airway exposures.
Regarding the present trends in HRCOPD, as opposed to
birth cohort effects, factors from within the study period
Figure 2 Monthly age- and sex-specific prevalence of hospitalisation required COPD 2002e2009.
Figure 1 Age- and sex-specific prevalence, incidence, and mortality of hospitalisation-required COPD in the beginning and end of
the study period.
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On the crest of a wave 1401probably also play a role. Above the age of about 85 years
HRCOPD decreases with increasing age. This might be
caused by a general reluctance to hospitalise the most
elderly subjects. In contrast, a possible gradual lowering of
the threshold for admitting the most elderly and fragile
subjects to hospital may have contributed to the HRCOPD
increases in the elderly age groups observed during the
study period (the right rolling of the wave).
However, during the study period the overall Danish
incidence of HRCOPD decreased and this was at least partly
caused by an increase in the admission severity threshold
restricting COPD hospitalisation to more severe cases.10
Furthermore, the increase in admission threshold was
associated with major cutbacks in the number of Danish
COPD hospital beds. Regardless of age, threshold changes
due to cutbacks would most likely decrease the HRCOPD
incidence. Hence, the large opposing age-specific trends
found in this study are unlikely to be explained by changes
in the admission severity threshold.
In the study period the treatment of COPD in Denmark
improved substantially. Among Danish first-time COPD
hospitalised patients, tiotropium, long-acting-beta-2-
agonists, and inhaled corticosteroids were increasingly
used.10 Meanwhile, in Danish respiratory departments, the
use of non-invasive ventilation (NPPV) gained currency.
Evidence shows that these treatments reduce mortality and
postpone the need for COPD hospitalisation.30e32 However,
no treatment trials have shown large opposing effects on
different age groups. Hence, regarding the observed
changes improved treatment is also unlikely to be a major
explanatory factor.
Even though earlier studies of the same time period have
shown an increase in the inpatient and one-year mortality
of Danish patients first-time hospitalised with COPD,10 this
study found a decreasing mortality of subjects prevalent
with HRCOPD. The increase in one-year mortality of
subjects with incident HRCOPD was most likely caused by
increasing case severity due to elevation of the admission
severity threshold. The coexistence of increasing one-year
mortality of incident subjects and decreasing mortality of
the prevalent subjects is only possible if survival increases
above one year after the first COPD hospitalisation.
However, it is most likely that one year after a COPD hos-
pitalisation the mortality rates of HRCOPD subjects
increasingly approach the mortality rates of the population
without HRCOPD. We found that the latter decreased even
more than the first, and this supports the above interpre-
tation. Also, most likely the improved pharmacological
treatment reduced mortality.
Ageing effects represent a third way of interpreting our
trend findings. Compared to the majority who die, people
who survive into very old age may be genetically different
in a way that renders them less susceptible to developing
COPD and which causes the incidence of HRCOPD to
decrease with very old age. This, however, does not explain
the decreases among people below 75 years of age.Strengths and limitations
Most population surveys are subject to bias from selection
of healthy participants. In order to reduce this bias theytend to exclude the oldest age groups. Furthermore, diag-
nostic COPD criteria and staging based on spirometry alone,
which are used in most population surveys, do not correlate
sufficiently with patients’ level of symptoms and
prognosis,33e35 and tend to overestimate COPD among the
elderly.36 The Danish combination of a homogenous equal
access healthcare system and national registers covering
every individual provided the opportunity of this 5.4 million
subject cohort study with full coverage of the oldest age
groups.37
The diagnoses obtained from the Danish National Patient
Registry were coded by the doctor responsible for the
discharge and validated in a 2008 nationwide study which
found a positive predictive value of 92% for COPD.24 In order
to obtain the best possible sensitivity and specificity, as
suggested in the validation paper we added the codes
J41e43 (chronic bronchitis and emphysema) to the COPD
definition. Hospitalisations coded with J41e43 did not
significantly differ from those coded with J44 (COPD).10
Despite the 92% positive predictive value of the COPD
diagnosis codes, misclassification is still a potential limita-
tion of our study, and no spirometry data were available to
further validate the diagnosis. Hence, some hospitalisations
may in error have been coded with COPD, but probably
more COPD caused hospitalisations were miscoded with
other diagnoses, mainly acute bronchitis, pneumonia,
respiratory failure, or cardiac failure.24 This would lead to
an underestimation of the HRCOPD prevalence. Such
underestimation might be some of the explanation for the
decreasing prevalence with very high age. This would be
the case if among all subjects hospitalised due to COPD
exacerbation the very old subjects were more likely to be
misdiagnosed. However, misclassification and diagnostic
drift are not likely to have produced the opposing trends
between age groups above and below 75 years of age.
For the interpretation of the study results it should be
kept in mind that during the study period an unknown
number of Danish subjects will likely have developed fatal
COPD although never admitted to hospital for this. This
number is difficult to assess using register data, mainly
because comorbidity related to COPD is often recorded as
the only cause of death.38
The prevalence of HRCOPD may vary among countries
because of different incidences of severe COPD exacerba-
tions, and different severity thresholds for admission to
hospital. The prevalence of COPD found in Denmark is
somewhat higher than in studies from the US,9,39,40 Norway,
Sweden,41 and France,8 and for decades the proportion of
daily smokers has been higher in Denmark relative to other
developed countries, especially among women.42 However,
the incidence and characteristics of Danish COPD hospital-
isations are similar to findings from other developed coun-
tries. For instance, the inpatient mortality, age, sex, and
length of stay regarding COPD hospitalisations are similar in
Denmark and the UK.1,10
Because of the unquantifiable effect of changes in the
COPD admission severity threshold, trend studies of
HRCOPD do not necessarily reflect changes in the burden
of COPD in the general population. However, subjects
hospitalised with COPD constitute the group of identified
COPD patients who consume the most healthcare
resources. Besides delivering reliable and accurate
1402 J. Lykkegaard et al.numbers for planners of healthcare initiatives, this study
also contributes to the understanding of COPD. Studies of
COPD in the most elderly are rare, and the finding that the
prevalence of COPD decreases with very high age is most
interesting and somewhat in contrast to present beliefs
about the nature of the disease.43 However, if our findings
can actually be mainly explained by birth cohort effects
and historical airway exposures, then our most important
finding is that in the near future the incidence and prev-
alence of HRCOPD will decrease substantially, and that
this will be merely because of birth cohort effects and not
as result of any sort of present healthcare initiatives. In
order to determine whether this is the case, further
research analysing age period cohort effects on HRCOPD is
needed.
Conclusion
Some 4% of the Danish population aged above 75 years have
been hospitalised with COPD. During the period from 2002
to 2009 the overall prevalence of hospitalisation-required
COPD remained constant. However, significant age-specific
trends indicate that within a few years, ageing of birth
cohorts with low COPD prevalence will lead to a substantial
decrease in the prevalence of hospitalisation-required
COPD.
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